北京大学第三医院心血管内科PI

Wenyao Wang, MD, PhD

Associate researcher

Department of Cardiology, Peking University Third Hospital

教育经历

博士，北京协和医学院，2011.08-2016.07

访问学者，纽约理工学院，2014.09-2015.06

学士，青岛大学医学院，2006.08-2011.07

Education

PhD，Peking Union Medical College，2011.08-2016.07

Visiting Scholar, New York Institute of Technology，2014.09-2015.06

MD，Qingdao University，2006.08-2011.07

科研及工作经历

2021.12至今 北京大学第三医院，副研究员

2016.08-2021.11 中国医学科学院阜外医院，住院医师、主治医师

Research and Clinical Word

2021.12-Present, Peking University Third Hospital, Associate Researcher

2016.08-2021.11, Fuwai Hospital, Chinese Academy of Medical Sciences, Resident and Attending Physician

获奖及荣誉

2023华夏医学科技奖科学技术奖一等奖（第二完成人）

2023年“北京市优秀青年人才”（北京市科委）

2021年“中青年心血管病学菁英—临床科研创新奖”（中华医学会）

2020年“北京市科技新星”（北京市科委）

Award and Honor

2023 Huaxia Medical Science and Technology Award First Prize

2023 "Beijing Outstanding Young Talents" (Beijing Municipal Science and Technology Commission)

2021 "Young and Middle-aged Cardiovascular Elite - Clinical Research Innovation Award" (Chinese Medical Association)

2020 "Beijing Nova Program" (Beijing Science and Technology Commission)

长期从事心血管代谢疾病发病机制、高危冠心病患者抗栓治疗两个领域的研究工作。在前期研究中，明确了甲状腺功能异常是心血管疾病发生、发展的独立危险因素，建立了指导临床实践的危险分层工具，并进一步深入探索相关分子机制和干预治疗方案；在冠心病高危患者中建立了安全有效的个体化抗血小板治疗策略。相关研究成果发表SCI论文30余篇，参编专著4部，申请发明专利3项。作为负责人主持国自然面上项目1项、国自然青年项目各1项以及北京市科委项目1项。作为课题骨干参与完成多项科研项目，包括“十三五”国家重点研发计划、“十二五”国家科技支撑计划、国自然重大研究计划等。目前为北京精准医学学会委员，担任多个国际学术期刊审稿人。

Dr Wang has been engaged in research on the pathogenesis of cardio-metabolic diseases and anti-thrombotic therapy in high-risk coronary heart disease patients. In previous studies, Dr Wang identified thyroid dysfunction as an independent risk factor for cardiovascular diseases and established risk stratification tools to guide clinical practice. He also explored the relevant molecular mechanisms and intervention therapy programs in the area of thyroid dysfunction and cardiovascular diseases. Dr Wang conducted RCT to explore a safe and effective individualized antiplatelet therapy strategy in high-risk coronary heart disease patients. As independent PI, he has received fundings from National Natural Science Foundation of China and Beijing Science and Technology Commission. He is currently a member of the Beijing Precision Medicine Society and serves as a reviewer for several international academic journals.

论文

1. Tang YD*#, Wang W*, Yang M, Zhang K, Chen J, Qiao S, Yan H, Wu Y, Huang X, Xu B, Gao R, Yang Y. Randomized Comparisons of Double-Dose Clopidogrel or Adjunctive Cilostazol versus Standard Dual Anti-platelet in Patients with High Post-Treatment Platelet Reactivity: Results of the CREATIVE Trial. Circulation. 2018.

2. Wang W*, Zhang X*, Gao J, Meng X, Wang J, Zhang K, Chen J, Qi J, Shao C, Tang YD#. Effects of levothyroxine in subclinical hypothyroidism and heart failure with reduced ejection fraction: An open-label randomized trial. Cell Reports Medicine 2024 Apr; 5, 101473

3. Jia Y, Liang J, Wang W*, Wei X, Xiao S, Robinson KA. Assessment of redundant randomized clinical trials among patients with ST segment elevation myocardial infarction. BMC Med. 2023 Feb 24;21(1):69.

4. Song J, Liu Y, Chen J, Yang J, Wen J, Gao J, Shao C, Wang W#, Tang YD#. Fibrosis-4 stage of liver fibrosis predicts cardiovascular outcomes in acute coronary syndrome patients with and without type 2 diabetes mellitus. Diabetes Res Clin Pract. 2023 Jan;195:110206.

5. Wang W*, Guan H^#, Gerdes AM, Iervasi G, Yang Y, Tang YD^#. Thyroid Status, Cardiac Function and Mortality in Patients with Idiopathic Dilated Cardiomyopathy. Journal of Clinical Endocrinology & Metabolism. 2015 Aug; 100(8):3210-8.

6. Zhang K*, Meng X*, Wang W*, Zheng J, An S, Wang S, Qi Y, Gao C, Tang YD#. Prognostic Value of Free Triiodothyronine Level in Patients With Hypertrophic Obstructive Cardiomyopathy. Journal of Clinical Endocrinology & Metabolism. 2018;103: 1198-1205.

7. Meng X, Wang XL, Zhang ZY, Zhang K, Gao J, Zheng JL, Wang JJ, Liu YP, Yang J, Li C, Zheng YT, Shao C, Wang WY#, Tang YD#.Association Between Thyroid Dysfunction and Incidence of Atrial Fibrillation in Patients With Hypertrophic Obstructive Cardiomyopathy. Front Endocrinol (Lausanne). 2022 Jul 4;13:875003.

8. Yang J, Wang Y, Xi Z, Ma Y, Shao C, Wang W#, Tang YD#.Remnant-Like Particle Cholesterol and the Risk of Major Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis. J Cardiovasc Dev Dis. 2022 Dec 11;9(12):452.

9. Meng X, Wang WY#, Gao J, Zhang K, Zheng J, Wang JJ, Liu Y, Shao C, Tang YD*. Hypertrophic Obstructive Cardiomyopathy: Comparison of Outcomes After Myectomy or Alcohol Ablation. Front Cardiovasc Med. 2022 Mar 14;9:755376.

10. Wang W*, Wang S, Zhang K, Chen J, Zhang X, Shao C, Li P, Tang YD#. Hypothyroidism is associated with clinical outcomes in patients with acute myocardial infarction: subgroup analysis of China PEACE study. Endocrine. 2021 Oct;74(1):128-137.

11. Liu Y*, Wang W*, Song J*, Zhang K, Xu B, Li P, Shao C, Yang M, Chen J, Tang YD^#. Association Between Lipoprotein(a) and Peri-procedural Myocardial Infarction in Patients With Diabetes Mellitus Who Underwent Percutaneous Coronary Intervention. Front Endocrinol (Lausanne). 2021 Feb 3;11:603922.

12. Wang W*, Guan H, Fang W, Zhang K, Gerdes AM, Iervasi G and Tang YD^#. Free Triiodothyronine Level Correlates with Myocardial Injury and Prognosis in Idiopathic Dilated Cardiomyopathy: Evidence from Cardiac MRI and SPECT/PET Imaging. Scientific Reports. 2016 Dec; 6:39811.

13. Wang W*, Shao C*, Zhang K, Xu B, Yang M, Chen J, Li P^#, Tang YD^#. CYP2C19 genotype has prognostic value in specific populations following coronary stenting. Ann Transl Med. 2021 Jul;9(13):1066.

14. Liu Y^*, Wang W^*, Song J, Zhang K, Wang K, Shao C, Li P, Xu B, Yang M, Chen J, Zheng J and Tang YD^#. Prognosis of spontaneous myocardial infarction and various definitions of periprocedural myocardial infarction in patients who underwent percutaneous coronary intervention. Int J Cardiol. 2021;333:60-68.

15. Wang W*, Zhang K*, Zhao W, Gerdes AM, Iervasi G, Tang YD^#. Free Triiodothyronine Level Correlates with Statin Responsiveness in Acute Myocardial Infarction. J Geriatr Cardiol. 2018 Apr;15(4):290-297.

16. Wang W*, Tang YD^#, Yang M, Cui C, Mu M, Qian J, Yang YJ. Free triiodothyronine level indicates the degree of myocardial injury in patients with acute ST-elevation myocardial infarction. Chin Med J (Engl). 2013 Oct; 126(20):3926-9.

17. Meng X*, Wang W*, Zhang K*, Qi Y, An S, Wang S, Zheng J, Kong J, Liu H, Wu J, Zhou Y, Gao C^#, Tang YD^#. Epicardial adipose tissue volume is associated with non-alcoholic fatty liver disease and cardiovascular risk factors in the general population. Ther Clin Risk Manag. 2018 Aug 23;14:1499-1506.

18. Zhang K*, Wang W, Zhao S, Katz SD, Iervasi G, Gerdes AM and Tang YD^#. Long-term prognostic value of combined free triiodothyronine and late gadolinium enhancement in nonischemic dilated cardiomyopathy. Clin Cardiol. 2018; 41:96-103.

19. Wang K*, Wang W, Zhang K, Gao J, Liu Y, Zheng J, Li P and Tang Y^#. Prognostic value of free triiodothyronine and N-terminal pro-B-type natriuretic peptide for patients with acute myocardial infarction undergoing percutaneous coronary intervention: a prospective cohort study. Ann Transl Med. 2021;9:294.

20. Zhao Y*, Wang W, Zhang K, Tang YD^#. Association Between Low T3 Syndrome and Poor Prognosis in Adult Patients With Acute Myocarditis. Front Endocrinol (Lausanne). 2021 Mar 8;12:571765.

21. Qi Y*, Wang W, Zhang K, An S, Wang S, Zheng J, Tang YD^#. Development and validation of Women Acute Myocardial Infarction in-Hospital Mortality Score (WAMI Score). Int J Cardiol. 2018 May 15;259:31-39.

22. Zhang X*, Wang WY, Zhang K, Tian J, Zheng JL, Chen J, An SM, Wang SY, Liu YP, Zhao Y, Wang JJ, Yang M, Tang YD^#. Efficacy and safety of levothyroxine (L-T4) replacement on the exercise capability in chronic systolic heart failure patients with subclinical hypothyroidism: Study protocol for a multi-center, open label, randomized, parallel group trial (ThyroHeart-CHF). Trials. 2019 Feb 19;20(1):143.